PARP1 and breast carcinoma: Collectively, these data suggest that SLX1 expression serves as a predictive biomarker of PARP inhibitor responsiveness and that targeting SLX1 represents an effective strategy to enhance the efficacy of PARP inhibitors in breast cancer.